Free Trial

10x Genomics (TXG) Earnings Date, Estimates & Call Transcripts

10x Genomics logo
$14.31 +1.02 (+7.67%)
(As of 11/22/2024 ET)

10x Genomics Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 20Estimated
Actual EPS
(Oct. 29)
-$0.30 Beat By $0.04
Consensus EPS
(Oct. 29)
-$0.34

10x Genomics announced Q3 2024 earnings on October 29, 2024, reporting an EPS of -$0.30, which topped the consensus estimate of -$0.34 by $0.04. Quarterly revenue fell 1.3% year-over-year to $151.65 million, below analysts' expectations of $158.84 million. With a trailing EPS of -$1.53, 10x Genomics' earnings are expected to grow next year, from ($1.40) to ($1.24) per share.

TXG Upcoming Earnings

10x Genomics' next earnings date is estimated for Thursday, February 20, 2025, based off prior year's reporting schedules.

Get 10x Genomics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 10x Genomics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

TXG Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TXG Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

10x Genomics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20241-$0.53-$0.53-$0.53
Q3 20242-$0.41-$0.31-$0.36
Q4 20242-$0.34-$0.30-$0.32
20245-$1.28-$1.14-$1.21
Q1 20251-$0.42-$0.42-$0.42
Q2 20251-$0.33-$0.33-$0.33
Q3 20251-$0.29-$0.29-$0.29
Q4 20251-$0.22-$0.22-$0.22
FY 20254($1.26)($1.26)($1.26)

10x Genomics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/20/2025
(Estimated)
------- 
10/29/2024Q3 2024-$0.34-$0.30+$0.04-$0.30$158.84M$151.65M        
8/8/2024Q2 2024-$0.47-$0.32+$0.15-$0.32$150.90M$153.10M
4/30/2024Q1 2024-$0.50-$0.50--$0.50$142.24M$141.01M      
2/15/2024Q4 2023-$0.36-$0.41 -$0.05-$0.41$182.73M$183.98M      
11/2/2023Q3 2023-$0.45-$0.51 -$0.06-$0.23$150.11M$153.64M  
8/3/2023Q2 2023-$0.39-$0.53 -$0.14-$0.53$139.97M$146.82M      
5/3/2023Q1 2023-$0.38-$0.44 -$0.06-$0.44$128.87M$134.29M      
2/15/2023Q4 2022-$0.29-$0.15+$0.14-$0.15$148.17M$156.20M        

10x Genomics Earnings - Frequently Asked Questions

10x Genomics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates. Learn more on TXG's earnings history.

10x Genomics issued an update on its FY 2024 earnings guidance on Tuesday, October, 29th. The company issued revenue guidance of $595.0 million-$605.0 million, compared to the consensus revenue estimate of $636.6 million.

In the previous quarter, 10x Genomics (NASDAQ:TXG) reported ($0.30) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.34) by $0.04. Learn more on analysts' earnings estimate vs. TXG's actual earnings.

The conference call for 10x Genomics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for 10x Genomics's latest earnings report can be read online.
Read Transcript

10x Genomics (NASDAQ:TXG) has a recorded annual revenue of $618.73 million.

10x Genomics (NASDAQ:TXG) has a recorded net income of -$255.10 million. TXG has generated -$1.53 earnings per share over the last four quarters.

10x Genomics's earnings are expected to grow from ($1.40) per share to ($1.24) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:TXG) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners